Hims & Hers missed Wall Street expectations on both revenue and earnings in Q1, reporting an unexpected loss as margin pressure and a more competitive weight-loss drug landscape weighed on results. The company cited strategic business changes as contributing factors to the revenue shortfall. Despite the stumble, management raised Q2 revenue guidance, offering a partial offset to the disappointing quarter.
The miss signals that Hims & Hers is feeling real pressure in the GLP-1 and weight-loss drug space — a market it entered aggressively with compounded semaglutide. Investors who bought into the telehealth and obesity-drug tailwind story need to reassess how durable that growth is as branded competitors and regulatory scrutiny tighten the window. The raised Q2 guidance may soften the blow, but margin erosion is a structural concern, not a one-quarter blip.
Q2 2025 earnings report (expected late July/early August): this is when Hims & Hers must deliver on its raised guidance or face another selloff. Watch also for any FDA announcements on compounded GLP-1 drug policy, which could directly affect what Hims & Hers is legally allowed to sell.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief